FDAapproval95% confidence
FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable approval decision relevant to Merck; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Infectious Disease · HIV-1
- Sub-indication
- General
Related signal: Merck Receives FDA Approval for IDVYNSO, Expands Oncology Pipeline and Animal Health Sales